Publications 2026

Wilson M, Pedersen SG, Langeland N, Cox RJ, Aukrust P, Dahl TB, Sandvig A, Wilhelmsen M (2026)
Tailored Individual Follow-Ups Versus a One-Day Group Course in Patients With Long COVID (Post- COVID-19 Condition): Protocol for a Randomized Controlled Trial
JMIR Res Protoc, 15, e74113
DOI 10.2196/74113, PubMed 41490577

Publications 2025

Massonnaud CR, Peiffer-Smadja N, Poignard P, Jamard S, Goehringer F, Danion F, Reignier J, de Castro N, Garot D, Lapique EL, Lacombe K, Tolsma V, Faure E, Malvy D, Staub T, Courjon J, Cazenave-Roblot F, Dyrhol Riise AM, Leturnier P, Martin-Blondel G, Roger C, Akinosoglou K, Vincent Le Moing, Piroth L, Sellier P et al. (2025)
Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in hospitalized COVID-19 patients: long-term results from the DisCoVeRy trial
Clin Microbiol Infect (in press)
DOI 10.1016/j.cmi.2025.12.014, PubMed 41429349

Tunheim G, Baranowska-Hustad M, Lund-Johansen F, Fossum E, Bhandari S, Kukule L, Møller TKR, Vikse EL, Bekkevold T, Oftung F, Robertson AH, Næss LM (2025)
SARS-CoV-2 Infection With Alpha B.1.1.7 Virus Induced Higher Antibody Responses Than Earlier Non-VOC Variants During the First Waves of the COVID-19 Pandemic in Norway
APMIS, 133 (12), e70102
DOI 10.1111/apm.70102, PubMed 41376258